drugset / Trial / NCT03341936
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
Phase 2
Active not recruiting
29 enrolled
Dana-Farber Cancer Institute
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of two immunotherapy drugs, as a possible treatment for locoregionally recurrent squamous cell carcinoma of the head and neck. The immunotherapy drugs involved in this study are: * Nivolumab (Opdivo™) * Lirilumab
Timeline
- Start
- 2018-03-15
- Primary completion
- 2021-07-06
- Completion
- 2026-07-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lirilumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |